Incyte Corp $ 85.42 0.88 (1.04%)
Warning! GuruFocus has detected 3 Severe warning signs with INCY. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Incyte Corp () from 1993 to Dec 02 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Incyte stock (INCY) PE ratio as of Dec 02 2020 is 0. More Details
Incyte PE Ratio (TTM) Historical Data
View and export this data going back to 1993. Start your Free Trial
Incyte PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:ALXN NAS:BMRN NAS:MRNA NAS:SGEN NAS:ALNY NAS:SRPT NAS:NBIX NAS:BNTX NAS:TECH NAS:ACAD OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 XKRX:068270 HKSE:02269 OCSE:GMAB HKSE:01177 SZSE:300122
Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.